Success Story: Precision Oral Drug Design Secures NIW Approval in Pharmaceutical Sciences
Client’s Testimonial:
“Thank you, Chen attorneys. It was such a pleasure working with your team.”
On February 17th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Formulation Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Senior Formulation Scientist
Country of Origin: Jordan
State of Residence at the Time of Filing: Missouri
Approval Notice Date: February 17th, 2026
Processing Time: 24 months, 15 days
Case Summary:
Medication adherence is often treated as a patient-behavior problem, but in many therapies, the real leverage lies upstream in formulation: whether an oral dosage form can deliver the right amount of drug, at the right time, with tolerable side effects. Our client, a pharmaceutical sciences researcher with a Ph.D. in Pharmaceutics, built a focused record around that practical challenge, creating and improving oral dosage forms designed to ensure precise administration of therapeutic agents to increase adherence, reduce side effects, and improve patient outcomes.
North America Immigration Law Group (Chen Immigration Law Associates) framed the endeavor as a public-health and system-efficiency story. The petition emphasized that better oral delivery is a mechanism for reducing avoidable complications and improving therapeutic effectiveness at the population scale, especially in areas where treatment success depends on consistent dosing and tolerability.
The record was particularly persuasive because the client’s work was already recognized as essential research within the field. The case documented 8 peer-reviewed journal articles (including 2 first-authored), 1 peer-reviewed conference paper, 1 abstract, and 1 book chapter, with 96 citations. NAILG translated these statistics into a straightforward adjudicator-facing point: independent researchers have repeatedly used her work to support their own investigations across topics tied to pharmaceutical delivery and clinically relevant applications, signaling independent reliance rather than isolated publication.
Peer trust strengthened the case. The client completed at least 21 reviews, including repeated invitations to review for major professional conference venues, which the case framed as evidence that organizers and editors relied on her judgment to evaluate other researchers’ work in oral medications and related technologies.
NAILG organized the petition around a clear theme: a researcher with the training to build precise oral dosage forms, a track record of peer-validated output that others cite and build upon, and sustained peer trust reflected in substantial reviewing activity, all aligned to an endeavor that improves adherence and outcomes through better drug delivery.